Videos

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses overall survival as an endpoint in ovarian cancer.

Natalie S. Callander, MD, Professor of Medicine, University of Wisconsin Carbone Cancer Center, discusses updates in the treatment of relapsed/refractory multiple myeloma.

Vancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo's laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. Dr. Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator. 

Vinod P. Balachandran, MD, Surgical Oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis to determine the unique antigen qualities of long-term survivors of pancreatic cancer during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the agents approved by the FDA for the treatment of mantle cell lymphoma (MCL), including acalabrutinib (Calquence) and bortezomib (Velcade).

Ralf Huss, MD, Chief Medical Officer of Definiens, discusses a new immuno-oncology panel introduced by Definiens during the The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. The goal of the panel is to standardize the immunoprofiling of tumors to better predict response to immuno-oncology treatment.

Matthew D. Galsky, MD, Professor of Medicine, Mount Sinai School of Medicine, discusses progression in patients with metastatic bladder cancer.

Kelly Paulson, MD, PhD, a fellow at Seattle Cancer Care Alliance, discusses single-cell RNA sequencing in merkel cell carcinoma during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.

Johanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses using immunotherapy for the treatment of patients with colorectal cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses results of the ALEX clinical trial, which compared alectinib (Alecensa) versus crizotinib (Xalkori) in patients with ALK+ non–small cell lung cancer (NSCLC).

Nilofer Azad, MD, associate professor, Johns Hopkins University, discusses preliminary results from the NCI-Match trial for nivolumab (Opdivo) in patients with mismatch repair-deficient cancers The Society for Immunotherapy of Cancer (SITC) 32^nd Annual Meeting.<br /> &nbsp;

Jennifer Wu, PhD, professor, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, discusses how soluble MIC can impact response to anti-CTLA-4 therapy during The Society for Immunotherapy of Cancer (SITC) 32^nd Annual Meeting.<br /> &nbsp;

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses appropriate treatment for patients with stage IV adenocarcinoma who do not harbor oncogenic drivers.

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the evolving paradigm of gastrointestinal cancers.

John O. Mascarenhas, MD, associate professor of medicine, Icahn School of Medicine at Mount Sinai Hospital, discusses the optimal use of ruxolitinib (Jakafi) and the improved understanding of JAK2 inhibition of polycythemia vera.

Ruben Mesa, MD, director, UT Health San Antonio Cancer Center, discusses NCCN guideline updates in polycythemia vera and essential thrombocythemia.

Jason Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the promising combination of a PD-1 antibody plus an IDO inhibitor for the treatment of patients with melanoma.<br /> &nbsp;

Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses overcoming resistance to endocrine therapy in ER+ breast cancer.

Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.

Matthew Kulke, MD, director, Neuroendocrine and Carcinoid Tumors Program, Dana-Farber Cancer Institute, discusses treatment options on the horizon in the treatment of neuroendocrine tumors (NETs) during the 2017 NANETS Symposium.

Sandy Wong, MD, assistant professor, Division of Hematology/Oncology, UCSF School of Medicine, discusses the progress that has been made with monocloncal antibodies for the treatment of plasma cell neoplasms.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in patients with acute myeloid leukemia (AML).

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the SWOG S1505 trial, which is exploring perioperative mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.

Julia Elvin, MD, PhD, vice president and senior associate medical director, Foundation Medicine, discusses a study that explored the different characteristics of subtypes of ovarian cancer, peritoneal tumors, and fallopian tube tumors.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing agents in chronic lymphocytic leukemia (CLL).

Celeste Lebb&eacute;, MD, from the H&ocirc;pital Saint Louis, in Paris, France, discusses the use of immunotherapy for the treatment of melanoma.

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with&nbsp;ROS1-positive non&ndash;small cell lung cancer (NSCLC).

Jennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses BRAF and MEK inhibitor combinations studies in melanoma.